Compass Therapeutics, Inc.
Cena
Kam smerujú tržby
Načítavam tok výkazu ziskov a strát…
Odkiaľ plynú tržby
Fundamenty
Načítavam kľúčové čísla…
Insideri, analytici a ľudia
Všetky obchody a zmenyNačítavam insiderov, analytikov a názory…
Co se právě děje
AI souhrnO spoločnosti
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Český popis pripravujeme.
- Zamestnanci
- 39
- Krajina
- USA
- Koniec fiškálneho roka
- 31. 12.
- Dáta od
- 5. 4. 2021